JP2007535498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535498A5 JP2007535498A5 JP2007502006A JP2007502006A JP2007535498A5 JP 2007535498 A5 JP2007535498 A5 JP 2007535498A5 JP 2007502006 A JP2007502006 A JP 2007502006A JP 2007502006 A JP2007502006 A JP 2007502006A JP 2007535498 A5 JP2007535498 A5 JP 2007535498A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- symptoms
- amount
- reduce
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 208000024891 symptom Diseases 0.000 claims 18
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 14
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 13
- 229960003776 glatiramer acetate Drugs 0.000 claims 13
- 230000004112 neuroprotection Effects 0.000 claims 13
- 201000006417 multiple sclerosis Diseases 0.000 claims 9
- 210000003169 central nervous system Anatomy 0.000 claims 8
- 210000001428 peripheral nervous system Anatomy 0.000 claims 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 7
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940042385 glatiramer Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54997404P | 2004-03-03 | 2004-03-03 | |
| US54997604P | 2004-03-03 | 2004-03-03 | |
| US54997504P | 2004-03-03 | 2004-03-03 | |
| PCT/US2005/007072 WO2005084377A2 (en) | 2004-03-03 | 2005-03-03 | Combination therapy with glatiramer acetate and riluzole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535498A JP2007535498A (ja) | 2007-12-06 |
| JP2007535498A5 true JP2007535498A5 (enExample) | 2008-04-17 |
Family
ID=34923270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007502006A Withdrawn JP2007535498A (ja) | 2004-03-03 | 2005-03-03 | グラチラマー・アセテートおよびリルゾールでの併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070244056A1 (enExample) |
| EP (1) | EP1778286A4 (enExample) |
| JP (1) | JP2007535498A (enExample) |
| AU (1) | AU2005218625A1 (enExample) |
| CA (1) | CA2558380A1 (enExample) |
| IL (1) | IL177845A0 (enExample) |
| WO (1) | WO2005084377A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| US8491890B2 (en) * | 2008-07-09 | 2013-07-23 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| KR20160038057A (ko) | 2009-08-20 | 2016-04-06 | 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 | 글라티라머 아세테이트를 포함하는 약제 |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP2627669B1 (en) | 2010-10-11 | 2016-08-17 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
| US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| KR102580378B1 (ko) * | 2014-11-21 | 2023-09-19 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 릴루졸의 설하 제제 |
| JP6827924B2 (ja) | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| SMT202500136T1 (it) | 2016-08-31 | 2025-05-12 | Mapi Pharma Ltd | Sistemi a deposito comprendenti glatiramer acetato |
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) * | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DE60017733T2 (de) * | 1999-06-04 | 2006-01-12 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Verwendung von riluzol zur behandlung multipler sklerose |
| US6872739B1 (en) * | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| EP1248643B1 (en) * | 2000-01-20 | 2005-08-17 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| CN1308683C (zh) * | 2001-12-04 | 2007-04-04 | 特瓦制药工业有限公司 | 测量醋酸格拉默功效的方法 |
| EP1429800B1 (en) * | 2001-12-06 | 2009-02-11 | Yeda Research And Development Co., Ltd. | Vaccine and use thereof for treatment of amyotrophic lateral sclerosis |
| JP3704711B2 (ja) * | 2003-06-20 | 2005-10-12 | 船井電機株式会社 | 液晶テレビジョン用台座 |
| NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
| DK1799703T3 (da) * | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
-
2005
- 2005-03-03 WO PCT/US2005/007072 patent/WO2005084377A2/en not_active Ceased
- 2005-03-03 AU AU2005218625A patent/AU2005218625A1/en not_active Abandoned
- 2005-03-03 JP JP2007502006A patent/JP2007535498A/ja not_active Withdrawn
- 2005-03-03 US US10/591,195 patent/US20070244056A1/en not_active Abandoned
- 2005-03-03 CA CA002558380A patent/CA2558380A1/en not_active Abandoned
- 2005-03-03 EP EP05724586A patent/EP1778286A4/en not_active Withdrawn
-
2006
- 2006-08-31 IL IL177845A patent/IL177845A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535498A5 (enExample) | ||
| MX347617B (es) | Formulaciones galenicas de compuestos organicos. | |
| WO2008062273A3 (en) | Solid oral dosage form having antidiabetic drug combination | |
| JP2005518433A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
| JP2008523153A5 (enExample) | ||
| JP2010174019A5 (enExample) | ||
| FI2629097T1 (fi) | Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia | |
| WO2004002999A8 (en) | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections | |
| WO2007056232B1 (en) | Methods of using saha and bortezomib for treating cancer | |
| WO2007084424A3 (en) | Treatment of substance abuse | |
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| WO2006116148A3 (en) | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse | |
| NZ597488A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| GEP20043383B (en) | Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds | |
| JP2006514611A5 (enExample) | ||
| WO2006103407A3 (en) | New pharmaceutical compositions useful in the treatment of migraine | |
| WO2007092326A3 (en) | Inhibition of hiv infection through chemoprophylaxis | |
| JP2001513506A5 (enExample) | ||
| SG158869A1 (en) | A tetracycline metal complex in a solid dosage form | |
| WO2005074536A3 (en) | Compositions and methods using proton pump inhibitors | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| WO2005117895A8 (en) | Compositions comprising meloxicam | |
| JP2011500589A5 (enExample) |